New PLA Codes Billable Under the Medicare CLFS to Be Aware Of
Here’s a quick briefing of the new codes that come into effect on April 1 that your billing staff should know about.
Labs that provide tests to beneficiaries covered by Medicare Part B need to be aware of upcoming Clinical Laboratory Fee Schedule (CLFS) changes. The Centers for Medicare & Medicaid Services (CMS) announced the changes in its quarterly Medicare Learning Network transmittal (CR 13082) on Feb. 2 and they officially take effect on April 1, 2023.1 One of the key changes that your billing staff may have to know about to ensure full and proper reimbursement is the addition of new Proprietary Laboratory Analysis (PLA) codes that Medicare will pay for under the CLFS. Here’s a quick briefing on the coding changes.
The Importance of PLA Codes
Proprietary Laboratory Analysis (PLA) codes are alpha numeric codes consisting of four digits and ending with the uppercase letter “U” that the AMA incorporated into its CPT coding system to enable labs or manufacturers to specifically identify their test products. PLA codes are assigned only if the lab or manufacturer requests them. PLA tests include:
-
- Advanced diagnostic laboratory tests (ADLTs)
-
- Clinical diagnostic laboratory tests (CDLTs) that are not ADLTs
-
- Multianalyte assays with algorithmic analyses (MAAA)
- Genomic sequencing procedures
PLA coded tests may be performed either by “one, sole source” lab or multiple labs to whom that lab licenses the test. Every year, CMS expands the list of PLA tests paid by Medicare. Initially, Medicare Administrative Contractors (MACs) decide on the price for PLA tests performed by labs in their jurisdiction until they’re nationally priced by CMS.
The New PLA Codes
Medicare will pay for 22 additional PLA tests, starting April 1, 2023:
New PLA Codes Added to CLFS, Effective April 1, 2023
| Laboratory | CPT Code | Long Descriptor | Short Descriptor |
| clonoSEQAssay, Adaptive Biotechnologies | 0364U | Oncology (hematolymphoid neoplasm), genomic sequence analysis using multiplex (PCR) and next-generation sequencing with algorithm, quantification of dominant clonal sequence(s), reported as presence or absence of minimal residual disease (MRD) with quantitation of disease burden, when appropriate | ONC HL NEO GEN SEQ ALYS ALG |
| Oncuria Detect, DiaCarta Clinical Lab, DiaCarta, Inc | 0365U | Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, algorithm reported as probability of bladder cancer | ONC BLDR 10 PRB BLDR CA |
| Oncuria Monitor, DiaCarta Clinical Lab, DiaCarta, Inc | 0366U | Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, algorithm reported as probability of recurrent bladder cancer | ONC BLDR 10 PRB RECR BLDR CA |
| Oncuria Predict, DiaCarta Clinical Lab, DiaCarta, Inc | 0367U | Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, diagnostic algorithm reported as risk score for probability of rapid recurrence of recurrent or persistent cancer following transurethral resection | ONC BLDR 10 FLWG TRURL RESCJ |
| GI assay (Gastrointestinal Pathogen with ABR), Lab Genomics LLC, Thermo Fisher Scientific | 0369U | Infectious agent detection by nucleic acid (DNA and RNA), gastrointestinal pathogens, 31 bacterial, viral, and parasitic organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique | IADNA GI PTHGN 31 ORG&21 ARG |
| Lesion Infection (Wound), Lab Genomics LLC, Thermo Fisher Scientific | 0370U | Infectious agent detection by nucleic acid (DNA and RNA), surgical wound pathogens, 34 microorganisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, wound swab | IADNA SURG WND PTHGN 34&21 |
| Qlear UTI, Lifescan Labs of Illinois, Thermo Fisher Scientific | 0371U | Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogen, semiquantitative identification, DNA from 16 bacterial organisms and 1 fungal organism, multiplex amplified probe technique via quantitative polymerase chain reaction (qPCR), urine | IADNA GU PTHGN SEMIQ DNA16&1 |
| Qlear UTI – Reflex ABR, Lifescan Labs of Illinois, Thermo Fisher Scientific | 0372U | Infectious disease (genitourinary pathogens), antibiotic-resistance gene detection, multiplex amplified probe technique, urine, reported as an antimicrobial stewardship risk score | NFCT DS GU PTHGN ARG DETCJ |
| Respiratory Pathogen with ABR (RPX), Lab Genomics LLC, Thermo Fisher Scientific | 0373U | Infectious agent detection by nucleic acid (DNA and RNA), respiratory tract infection, 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes, multiplex amplified probe technique, upper or lower respiratory specimen | IADNA RSP TR NFCT 17 8 13&16 |
| Urogenital Pathogen with Rx Panel (UPX), Lab Genomics LLC, Thermo Fisher Scientific | 0374U | Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 21 bacterial and fungal organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, urine | IADNA GU PTHGN 21 ORG&21ARG |
| OvaWatchSM, Aspira Women’s HealthSM, Aspira Labs, Inc | 0375U | Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [i.e., transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score | ONC OVRN BCHM ASY 7 PRTN ALG |
| ArteraAI Prostate Test, Artera Inc | 0376U | Oncology (prostate cancer), image analysis of at least 128 histologic features and clinical factors, prognostic algorithm determining risk of distant metastases, and prostate cancer-specific mortality, includes predictive algorithm to androgen deprivation therapy response, if appropriate | ONC PRST8 CA IMG ALYS 128 |
| Liposcale, CIMA Sciences, LLC | 0377U | Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (NMR) spectrometry with report of a lipoprotein profile (including 23 variables) | CV DS QUAN ADVSRM/PLSM LPRTN |
| UCGSL RFC1 Repeat Expansion Test, University of Chicago Genetic Services Laboratories | 0378U | RFC1 (replication factor C subunit 1), repeat expansion variant analysis by traditional and repeat-primed PCR, blood, saliva, or buccal swab | RFC1 REPEAT XPNSJ VRNT ALYS |
| Solid Tumor Expanded Panel, Quest Diagnostics | 0379U | Targeted genomic sequence analysis panel, solid organ neoplasm, DNA (523 genes) and RNA (55 genes) by next generation sequencing, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutational burden | TGSAP SL OR NEO DNA523&RNA55 |
| PersonalisedRX, Lab Genomics LLC, Agena Bioscience, Inc | 0380U | Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis, 20 gene variants and CYP2D6 deletion or duplication analysis with reported genotype and phenotype | RX METB ADVRS TRGT SQ ALY 20 |
| Branched-Chain Amino Acids, SelfCollect, Blood Spot, Mayo Clinic, Laboratory Developed Test | 0381U | Maple syrup urine disease monitoring by patient-collected blood card sample, quantitative measurement of alloisoleucine, leucine, isoleucine, and valine, liquid chromatography with tandem mass spectrometry (LC-MS/MS) | MAPLE SYRUP UR DS MNTR QUAN |
| Phenylalanine and Tyrosine, SelfCollect, Blood Spot, Mayo Clinic, Laboratory Developed Test | 0382U | Hyperphenylalaninemia monitoring by patient-collected blood card sample, quantitative measurement of phenylalanine and tyrosine, liquid chromatography with tandem mass spectrometry (LC-MS/MS) | HYPRPHENYLALNI NMIA MNTR QUAN |
| Tyrosinemia FollowUp Panel, SelfCollect, Blood Spot, Mayo Clinic, Laboratory Developed Test | 0383U | Tyrosinemia type I monitoring by patient-collected blood card sample, quantitative measurement of tyrosine, phenylalanine, methionine, succinylacetone, nitisinone, liquid chromatography with tandem mass spectrometry (LC-MS/MS) | TYROSINEMIA TYP I MNTR QUAN |
| NaviDKDTM Predictive Diagnostic Screening for Kidney Health, Journey Biosciences, Inc | 0384U | Nephrology (chronic kidney disease), carboxymethyllysine, methylglyoxal hydroimidazolone, and carboxyethyl lysine by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and HbA1c and estimated glomerular filtration rate (GFR), with risk score reported for predictive progression to high-stage kidney disease | NEPH CKD RSK HI STG KDN DS |
| PromarkerD, Sonic Reference Laboratory, Proteomics International Pty Ltd | 0385U | Nephrology (chronic kidney disease), apolipoprotein A4 (ApoA4), CD5 antigen-like (CD5L), and insulin-like growth factor binding protein 3 (IGFBP3) by enzyme-linked immunoassay (ELISA), plasma, algorithm combining results with HDL, estimated glomerular filtration rate (GFR) and clinical data reported as risk score for developing diabetic kidney disease | NEPH CKD ALG RSK DBTC KDN DS |
| Envisage, Capsulomics, Inc | 0386U | Gastroenterology (Barrett’s esophagus), P16, RUNX3, HPP1, and FBN1 methylation analysis, prognostic and predictive algorithm reported as a risk score for progression to high-grade dysplasia or esophageal cancer | GI BARRETT ESOPH MTHYLTN ALY |
CMS also removed two discontinued HCPCS codes from the CLFS:
-
- 0324U (Oncology (ovarian), spheroid cell culture, 4-drug panel (carboplatin, doxorubicin, gemcitabine, paclitaxel), tumor chemotherapy response prediction for each drug); and
- 0325U (Oncology (ovarian), spheroid cell culture, poly (ADPribose) polymerase (PARP) inhibitors (niraparib, olaparib, rucaparib, velparib), tumor response prediction for each drug.1
References:
Subscribe to view Essential
Start a Free Trial for immediate access to this article